Vanda Pharmaceuticals (VNDA) Stock Forecast, Price Target & Predictions
VNDA Stock Forecast
Vanda Pharmaceuticals stock forecast is as follows: an average price target of $11.00 (represents a 115.69% upside from VNDA’s last price of $5.10) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VNDA Price Target
The average price target for Vanda Pharmaceuticals (VNDA) is $11.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 115.69% upside from VNDA's last price of $5.10.
VNDA Analyst Ratings
According to 2 Wall Street analysts, Vanda Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VNDA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vanda Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 11, 2024 | Charles Duncan | Cantor Fitzgerald | $11.00 | $5.21 | 111.13% | 115.69% |
The latest Vanda Pharmaceuticals stock forecast, released on Jul 11, 2024 by Charles Duncan from Cantor Fitzgerald, set a price target of $11.00, which represents a 111.13% increase from the stock price at the time of the forecast ($5.21), and a 115.69% increase from VNDA last price ($5.10).
Vanda Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $11.00 | $11.00 |
| Last Closing Price | $5.10 | $5.10 | $5.10 |
| Upside/Downside | -100.00% | 115.69% | 115.69% |
In the current month, the average price target of Vanda Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vanda Pharmaceuticals's last price of $5.10. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 11, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Vanda Pharmaceuticals's last stock rating was published by Cantor Fitzgerald on Jul 11, 2024. The company Initialise its VNDA rating from "null" to "Overweight".
Vanda Pharmaceuticals Financial Forecast
Vanda Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $38.81M | $46.06M | $62.50M | $64.48M | $65.32M | - | $60.19M | $68.02M | $70.09M | $67.90M | $62.67M | $67.65M | $60.31M | $62.21M | $58.00M | $60.93M | $59.48M | $59.06M | $47.71M | $53.04M | $49.13M |
| Avg Forecast | $87.65M | $80.75M | $71.65M | $64.30M | $52.85M | $50.75M | $47.90M | $48.50M | $37.00M | $44.50M | $49.00M | $73.37M | $67.60M | $71.00M | $67.00M | $58.00M | $70.04M | $74.25M | $69.75M | $64.20M | $64.00M | $64.20M | $61.95M | $56.87M | $59.58M | $58.33M | $54.18M | $51.74M | $2.79M | $11.34M |
| High Forecast | $90.64M | $83.50M | $74.09M | $66.49M | $54.65M | $52.48M | $49.53M | $50.15M | $38.26M | $46.02M | $50.67M | $88.04M | $69.91M | $73.42M | $67.00M | $58.00M | $70.04M | $74.25M | $69.75M | $64.20M | $64.00M | $64.20M | $61.95M | $56.87M | $59.58M | $58.33M | $54.18M | $51.74M | $3.35M | $13.61M |
| Low Forecast | $84.66M | $78.00M | $69.21M | $62.11M | $51.05M | $49.02M | $46.27M | $46.85M | $35.74M | $42.98M | $47.33M | $58.70M | $65.29M | $68.58M | $67.00M | $58.00M | $70.04M | $74.25M | $69.75M | $64.20M | $64.00M | $64.20M | $61.95M | $56.87M | $59.58M | $58.33M | $54.18M | $51.74M | $2.23M | $9.07M |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 1 | - | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 0.94% | 0.85% | 0.95% | 0.92% | - | 1.04% | 0.97% | 0.94% | 0.97% | 0.98% | 1.06% | 0.94% | 1.00% | 1.02% | 1.02% | 1.02% | 1.09% | 0.92% | 19.00% | 4.33% |
Vanda Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 1 analysts is $37.00M, with a low forecast of $35.74M, and a high forecast of $38.26M. VNDA's average Quarter revenue forecast represents a -4.68% decrease compared to the company's last Quarter revenue of $38.81M (Sep 23).
Vanda Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 1 | - | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 20 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-6.00M | $-2.87M | $2.67M | $7.01M | $4.29M | - | $-6.97M | $9.32M | $11.43M | $13.32M | $11.14M | $10.16M | $9.12M | $11.80M | $1.96M | $6.54M | $13.00M | $12.26M | $110.00K | $11.07M | $8.01M |
| Avg Forecast | $6.39M | $5.89M | $5.23M | $4.69M | $3.86M | $3.70M | $3.49M | $-80.75M | $2.70M | $3.25M | $3.58M | $-73.41M | $4.93M | $16.34M | $4.89M | $-58.03M | $6.21M | $14.86M | $13.32M | $11.14M | $9.43M | $8.21M | $21.24M | $4.15M | $8.33M | $4.26M | $3.95M | $212.14K | $203.68K | $827.28K |
| High Forecast | $6.61M | $6.09M | $5.41M | $4.85M | $3.99M | $3.83M | $3.61M | $-64.60M | $2.79M | $3.36M | $3.70M | $-58.72M | $5.10M | $19.61M | $4.89M | $-46.42M | $7.45M | $17.83M | $15.98M | $13.37M | $11.32M | $9.85M | $25.49M | $4.15M | $10.00M | $4.26M | $3.95M | $254.57K | $244.41K | $992.74K |
| Low Forecast | $6.18M | $5.69M | $5.05M | $4.53M | $3.72M | $3.58M | $3.38M | $-96.90M | $2.61M | $3.14M | $3.45M | $-88.09M | $4.76M | $13.08M | $4.89M | $-69.63M | $4.97M | $11.89M | $10.65M | $8.91M | $7.55M | $6.57M | $16.99M | $4.15M | $6.66M | $4.26M | $3.95M | $169.71K | $162.94K | $661.82K |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.85% | -0.80% | -0.04% | 1.42% | 0.26% | - | 0.12% | 1.50% | 0.77% | 1.00% | 1.00% | 1.08% | 1.11% | 0.56% | 0.47% | 0.79% | 3.06% | 3.10% | 0.52% | 54.35% | 9.68% |
0 analysts predict VNDA's average Quarter EBITDA for Jun 23 to be $3.58M, with a high of $3.70M and a low of $3.45M. This is 33.70% upper than Vanda Pharmaceuticals's previous annual EBITDA (Mar 23) of $2.67M.
Vanda Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 1 | - | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 20 |
| Net Income | - | - | - | - | - | - | - | - | - | $137.00K | $1.52M | $3.25M | $6.86M | $3.27M | - | $-6.43M | $7.08M | $7.77M | $9.65M | $8.65M | $8.19M | $5.95M | $8.71M | $486.00K | $4.22M | $100.42M | $11.53M | $-612.00K | $10.36M | $7.17M |
| Avg Forecast | $8.73M | $6.40M | $2.04M | $-2.04M | $-9.90M | $-9.02M | $-11.06M | $-72.47M | $-5.24M | $-2.33M | $-7.57M | $-65.88M | $4.66M | $11.11M | $8.09M | $-52.08M | $4.72M | $10.10M | $9.65M | $8.65M | $7.61M | $5.35M | $15.69M | $-1.73M | $5.37M | $2.19B | $2.49M | $-1.18M | $158.51M | $40.87M |
| High Forecast | $9.12M | $6.69M | $2.13M | $-1.95M | $-9.46M | $-8.62M | $-10.57M | $-57.98M | $-5.01M | $-2.23M | $-7.23M | $-52.71M | $4.86M | $13.34M | $8.09M | $-41.67M | $5.66M | $12.12M | $11.58M | $10.38M | $9.13M | $6.42M | $18.82M | $-1.73M | $6.44M | $2.63B | $2.49M | $-944.23K | $190.21M | $49.05M |
| Low Forecast | $8.35M | $6.12M | $1.95M | $-2.13M | $-10.34M | $-9.42M | $-11.55M | $-86.97M | $-5.47M | $-2.43M | $-7.90M | $-79.06M | $4.45M | $8.89M | $8.09M | $-62.50M | $3.77M | $8.08M | $7.72M | $6.92M | $6.08M | $4.28M | $12.55M | $-1.73M | $4.29M | $1.76B | $2.49M | $-1.42M | $126.81M | $32.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.06% | -0.20% | -0.05% | 1.47% | 0.29% | - | 0.12% | 1.50% | 0.77% | 1.00% | 1.00% | 1.08% | 1.11% | 0.56% | -0.28% | 0.79% | 0.05% | 4.62% | 0.52% | 0.07% | 0.18% |
Vanda Pharmaceuticals's average Quarter net income forecast for Dec 23 is $-5.24M, with a range of $-5.47M to $-5.01M. VNDA's average Quarter net income forecast represents a -3924.73% decrease compared to the company's last Quarter net income of $137.00K (Sep 23).
Vanda Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 1 | - | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 20 |
| SG&A | - | - | - | - | - | - | - | - | - | $24.77M | $28.40M | $36.10M | $32.78M | $29.85M | - | $40.85M | $33.45M | $32.46M | $28.35M | $29.80M | $59.30M | $34.37M | $34.29M | $37.39M | $37.39M | $30.60M | $31.85M | $31.41M | $25.30M | $26.44M |
| Avg Forecast | $47.71M | $43.95M | $39.00M | $35.00M | $28.77M | $27.62M | $26.07M | $26.40M | $20.14M | $24.22M | $26.67M | $39.93M | $36.79M | $46.41M | $36.47M | $31.57M | $22.30M | $42.19M | $28.35M | $29.80M | $55.07M | $30.93M | $61.71M | $30.95M | $47.58M | $31.75M | $29.49M | $28.16M | $1.52M | $6.17M |
| High Forecast | $49.33M | $45.45M | $40.33M | $36.19M | $29.75M | $28.56M | $26.96M | $27.30M | $20.83M | $25.05M | $27.58M | $47.92M | $38.05M | $55.69M | $36.47M | $31.57M | $26.76M | $50.63M | $34.02M | $35.76M | $66.08M | $37.12M | $74.06M | $30.95M | $57.10M | $31.75M | $29.49M | $28.16M | $1.82M | $7.41M |
| Low Forecast | $46.08M | $42.45M | $37.67M | $33.80M | $27.78M | $26.68M | $25.18M | $25.50M | $19.45M | $23.39M | $25.76M | $31.95M | $35.54M | $37.13M | $36.47M | $31.57M | $17.84M | $33.75M | $22.68M | $23.84M | $44.06M | $24.75M | $49.37M | $30.95M | $38.07M | $31.75M | $29.49M | $28.16M | $1.22M | $4.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.06% | 0.90% | 0.89% | 0.64% | - | 1.29% | 1.50% | 0.77% | 1.00% | 1.00% | 1.08% | 1.11% | 0.56% | 1.21% | 0.79% | 0.96% | 1.08% | 1.12% | 16.65% | 4.28% |
Vanda Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $20.14M, based on 1 Wall Street analysts, with a range of $19.45M to $20.83M. The forecast indicates a -18.69% fall compared to VNDA last annual SG&A of $24.77M (Sep 23).
Vanda Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 1 | - | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 20 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.03 | $0.06 | $0.12 | $0.06 | - | $-0.11 | $0.13 | $0.14 | $0.17 | $0.16 | $0.15 | $0.11 | $0.16 | $0.01 | $0.08 | $1.88 | $0.22 | $-0.01 | $0.20 | $0.14 |
| Avg Forecast | $0.15 | $0.11 | $0.04 | $-0.04 | $-0.17 | $-0.15 | $-0.19 | $0.05 | $-0.09 | $-0.04 | $-0.13 | $-0.10 | $0.08 | $0.10 | $0.14 | $-0.01 | $0.09 | $0.19 | $0.15 | $0.08 | $0.14 | $0.10 | $0.06 | $-0.03 | $0.08 | $0.07 | $0.04 | $0.07 | $0.15 | $-0.17 |
| High Forecast | $0.16 | $0.11 | $0.04 | $-0.03 | $-0.16 | $-0.15 | $-0.18 | $0.05 | $-0.09 | $-0.04 | $-0.12 | $-0.08 | $0.08 | $0.10 | $0.14 | $-0.01 | $0.09 | $0.19 | $0.15 | $0.08 | $0.14 | $0.10 | $0.06 | $-0.03 | $0.08 | $0.07 | $0.04 | $0.07 | $0.18 | $-0.14 |
| Low Forecast | $0.14 | $0.11 | $0.03 | $-0.04 | $-0.18 | $-0.16 | $-0.20 | $0.05 | $-0.09 | $-0.04 | $-0.14 | $-0.13 | $0.08 | $0.10 | $0.14 | $-0.01 | $0.09 | $0.19 | $0.15 | $0.08 | $0.14 | $0.10 | $0.06 | $-0.03 | $0.08 | $0.07 | $0.04 | $0.07 | $0.12 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.06% | -0.20% | -0.57% | 1.50% | 0.60% | - | 11.00% | 1.53% | 0.74% | 1.13% | 2.00% | 1.06% | 1.15% | 2.90% | -0.33% | 1.00% | 25.07% | 5.08% | -0.14% | 1.33% | -0.82% |
According to 1 Wall Street analysts, Vanda Pharmaceuticals's projected average Quarter EPS for Dec 23 is $-0.09, with a low estimate of $-0.09 and a high estimate of $-0.09. This represents a -3850.00% decrease compared to VNDA previous annual EPS of - (Sep 23).
Vanda Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| VNDA | Vanda Pharmaceuticals | $5.10 | $11.00 | 115.69% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| RCUS | Arcus Biosciences | $17.95 | $35.20 | 96.10% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| LQDA | Liquidia | $9.80 | $17.17 | 75.20% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| PHAT | Phathom Pharmaceuticals | $18.30 | $25.83 | 41.15% | Buy |
| TECH | Bio-Techne | $74.67 | $99.21 | 32.86% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| CNTB | Connect Biopharma | $1.23 | $1.50 | 21.95% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| TSVT | 2seventy bio | $4.71 | $2.00 | -57.54% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
VNDA Forecast FAQ
Is Vanda Pharmaceuticals a good buy?
Yes, according to 2 Wall Street analysts, Vanda Pharmaceuticals (VNDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of VNDA's total ratings.
What is VNDA's price target?
Vanda Pharmaceuticals (VNDA) average price target is $11 with a range of $11 to $11, implying a 115.69% from its last price of $5.1. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vanda Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for VNDA stock, the company can go up by 115.69% (from the last price of $5.1 to the average price target of $11), up by 115.69% based on the highest stock price target, and up by 115.69% based on the lowest stock price target.
Can Vanda Pharmaceuticals stock reach $8?
VNDA's average twelve months analyst stock price target of $11 supports the claim that Vanda Pharmaceuticals can reach $8 in the near future.
What are Vanda Pharmaceuticals's analysts' financial forecasts?
Vanda Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $200M (high $206.82M, low $193.18M), average EBITDA is $-69.693M (high $-53.167M, low $-86.219M), average net income is $-102M (high $-86.633M, low $-118M), average SG&A $108.86M (high $112.57M, low $105.15M), and average EPS is $-0.465 (high $-0.44, low $-0.49). VNDA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $304.35M (high $314.73M, low $293.97M), average EBITDA is $22.21M (high $22.96M, low $21.45M), average net income is $15.14M (high $15.99M, low $14.29M), average SG&A $165.65M (high $171.3M, low $160.01M), and average EPS is $0.26 (high $0.275, low $0.245).
Did the VNDA's actual financial results beat the analysts' financial forecasts?
Based on Vanda Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $192.64M, which missed the average analysts forecast of $203.87M by -5.51%. Apple's EBITDA was $-13.952M, missing the average prediction of $-63.885M by -78.16%. The company's net income was $2.51M, missing the average estimation of $-81.022M by -103.10%. Apple's SG&A was $112.88M, beating the average forecast of $110.96M by 1.73%. Lastly, the company's EPS was $0.0436, missing the average prediction of $-0.36 by -112.12%. In terms of the last quarterly report (Sep 2023), Vanda Pharmaceuticals's revenue was $38.82M, missing the average analysts' forecast of $44.5M by -12.78%. The company's EBITDA was $-5.995M, missing the average prediction of $3.25M by -284.65%. Vanda Pharmaceuticals's net income was $137K, missing the average estimation of $-2.329M by -105.88%. The company's SG&A was $24.77M, beating the average forecast of $24.22M by 2.25%. Lastly, the company's EPS was $0.0024, missing the average prediction of $-0.04 by -106.00%